Evidence map›Paper›PMID 37118382›Full record

ArticleMolecular biology reports2023

Enhancement of mesenchymal stem cells' chondrogenic potential by type II collagen-based bioscaffolds.

Zoi Piperigkou, Dimitra Bainantzou, Nadia Makri, Eleni Papachristou, Aglaia Mantsou, Theodora Choli-Papadopoulou, Achilleas D Theocharis, Nikos K Karamanos

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review.International journal of molecular sciences · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zoi PiperigkouBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.ORCID http://orcid.org/0000-0002-0472-5389
Dimitra BainantzouBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.
Nadia MakriBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece.
Eleni PapachristouLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aglaia MantsouLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Theodora Choli-PapadopoulouLaboratory of Biochemistry, Department of Chemistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-7459-5807
Achilleas D TheocharisBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece. atheoch@upatras.gr.ORCID http://orcid.org/0000-0001-8611-2297
Nikos K KaramanosBiochemistry, Biochemical Analysis and Matrix Pathobiology Research Group, Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece. n.k.karamanos@upatras.gr.ORCID http://orcid.org/0000-0003-3618-0288
University of Patras · GRAristotle University of Thessaloniki · GR

Funding

European Union and Greek national funds EntrepreneurshipEuropean Union and Greek national funds Greek national funds through the Operational Program CompetitivenessEuropean Union and Greek national funds InnovationEuropean Union and Greek national funds This research has been co-financed by the European Regional Development Fund of the European UnionEuropean Union and Greek national funds under the call RESEARCH - CREATE - INNOVATE (project code: T1EDK-04567)
6 · The paper itself

Abstract

backgroundOsteoarthritis (OA) is a common degenerative chronic disease accounting for physical pain, tissue stiffness and mobility restriction. Current therapeutic approaches fail to prevent the progression of the disease considering the limited knowledge on OA pathobiology. During OA progression, the extracellular matrix (ECM) of the cartilage is aberrantly remodeled by chondrocytes. Chondrocytes, being the main cell population of the cartilage, participate in cartilage regeneration process. To this end, modern tissue engineering strategies involve the recruitment of mesenchymal stem cells (MSCs) due to their regenerative capacity as to promote chondrocyte self-regeneration. METHODS AND

resultsIn the present study, we evaluated the role of type II collagen, as the main matrix macromolecule in the cartilage matrix, to promote chondrogenic differentiation in two MSC in vitro culture systems. The chondrogenic differentiation of human Wharton's jelly- and dental pulp-derived MSCs was investigated over a 24-day culture period on type II collagen coating to improve the binding affinity of MSCs. Functional assays, demonstrated that type II collagen promoted chondrogenic differentiation in both MSCs tested, which was confirmed through gene and protein analysis of major chondrogenic markers.

conclusionsOur data support that type II collagen contributes as a natural bioscaffold enhancing chondrogenesis in both MSC models, thus enhancing the commitment of MSC-based therapeutic approaches in regenerative medicine to target OA and bring therapy closer to the clinical use.

Indexed as

Cell Culture TechniquesChondrocytesMesenchymal Stem CellsCell- and Tissue-Based TherapyCollagen Type IIDental PulpHumansMatrix MetalloproteinasesOsteoarthritisPrimary Cell CultureTissue Inhibitor of MetalloproteinasesUmbilical CordCollagen Type IIMatrix MetalloproteinasesTissue Inhibitor of MetalloproteinasesChondrogenic differentiationExtracellular matrixMesenchymal stem cellsMolecular targetingOsteoarthritisType II collagen

Identifiers

PMID37118382
PMCPMC10209287
OpenAlexW4367309543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.